AUGMENTATION STRATEGIES FOR TREATMENT-RESISTANT OBSESSIVE-COMPULSIVE DISORDER

被引:10
|
作者
JENIKE, MA
机构
[1] HARVARD UNIV,SCH MED,BOSTON,MA 02115
[2] MASSACHUSETTS GEN HOSP,BOSTON,MA 02114
关键词
D O I
10.3109/10673229309017053
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
This review discusses augmentation strategies for patients with obsessive-compulsive disorder who fail to respond to treatment. A patient's failure to respond to treatment may be due to any of a number of factors, such as noncompliance with a behavioral program, concurrent severe depression or personality disorder, certain ritualistic behaviors, inaccurate diagnosis, and inadequate treatment. It is particularly important that comorbid psychiatric disorders be diagnosed and treated. A review of the literature and my experience with the use of augmenting agents such as lithium, buspirone, clonidine, fenfluramine, antidepressants, anxiolytic agents, and neuroleptics in treatment-resistant obsessive-compulsive disorder are presented. Existing evidence suggests that some of these approaches are useful for some patients. However, many questions remain, and much research remains to be done on this topic.
引用
收藏
页码:17 / 26
页数:10
相关论文
共 50 条
  • [31] Aripiprazole Augmentation of Clomipramine Therapy in Treatment-Resistant Obsessive-Compulsive Disorder: Case Series
    Izci, Filiz
    Yalcin, Murat
    Calli, Sumeyye Yasemin Kurtulus
    Sever, Yagmur
    Bilici, Rabia
    [J]. DUSUNEN ADAM-JOURNAL OF PSYCHIATRY AND NEUROLOGICAL SCIENCES, 2016, 29 (02): : 163 - 168
  • [32] Effect of ziprasidone augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder
    Curro, V.
    Bruno, A.
    Pandolfo, G.
    Scimeca, G.
    Muscatello, M. R. A.
    Zoccali, R. A.
    [J]. EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S524 - S524
  • [33] Memantine Augmentation in Treatment-Resistant Obsessive-Compulsive Disorder An Open-Label Trial
    Aboujaoude, Elias
    Barry, John J.
    Gamel, Nona
    [J]. JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2009, 29 (01) : 51 - 55
  • [34] Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: An open-label trial
    Coric, V
    Taskiran, S
    Pittenger, C
    Wasylink, S
    Mathalon, DH
    Valentine, G
    Saksa, J
    Wu, YT
    Gueorguieva, R
    Sanacora, R
    Malison, RT
    Krystal, JH
    [J]. BIOLOGICAL PSYCHIATRY, 2005, 58 (05) : 424 - 428
  • [35] Trauma and posttraumatic stress disorder in treatment-resistant obsessive-compulsive disorder
    Gershuny, Beth S.
    Baer, Lee
    Parker, Holly
    Gentes, Emily L.
    Infield, Alison L.
    Jenike, Michael A.
    [J]. DEPRESSION AND ANXIETY, 2008, 25 (01) : 69 - 71
  • [36] Treatment-resistant obsessive-compulsive disorders
    Endres, Dominique
    Jelinek, Lena
    Domschke, Katharina
    Voderholzer, Ulrich
    [J]. NERVENARZT, 2024, 95 (05): : 432 - 439
  • [37] Treatment-Resistant Obsessive-Compulsive Disorder: Neurocognitive and Clinical Correlates
    Dinn, Wayne M.
    Aycicegi-Dinn, Ayse
    Goral, Fatma
    Darkal, Ola
    Yildirim, Ejder Akgun
    Hacioglu, Munevver
    [J]. FUTURE ACADEMY MULTIDISCIPLINARY CONFERENCE ICEEPSY & CPSYC & ICPSIRS & BE-CI, 2016, 217 : 1189 - 1198
  • [38] Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder
    Hollander, E
    Dell'Osso, B
    [J]. INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2006, 21 (03) : 189 - 191
  • [39] Treatment-Resistant Obsessive-Compulsive Disorder: Clinical and Personality Correlates
    Dinn, Wayne M.
    Aycicegi-Dinn, Ayse
    Goral, Fatma
    Yildirim, Ejder Akgun
    Hacioglu, Munevver
    [J]. 5TH WORLD CONFERENCE ON PSYCHOLOGY, COUNSELING AND GUIDANCE, WCPCG-2014, 2014, 159 : 239 - 242
  • [40] Lumateperone monotherapy for treatment-resistant obsessive-compulsive disorder in an adolescent
    Naguy, Ahmed
    Pridmore, Saxby
    Abuzeid, Mohamed Y.
    Elsori, Dalal
    Alamiri, Bibi
    [J]. CNS SPECTRUMS, 2024, 29 (01) : 4 - 5